Design, synthesis and structure of peptides and proteins news

18 Jul 2017

In an interview on the programme “Valencia en la Onda”, presented by Mª Paz Fernández on Radio Onda Cero, Meritxell Teixidó, research associate at IRB Barcelona, talks about his research at the Design, Synthesis and Structure of Peptides and Proteins Laboratory. 

During the interview, Teixidó explains the Lab's work on transforming a protein from bee venom into a tool that helps treatments get inside the brain and can be applied to treat central nervous system diseases.

<p>Image: 24Hours Naija News.</p>
17 Jul 2017

The Nigerian website "24Hours Naija News" devotes a report to the use of insects such as termites and grasshoppers in the treatment of cancer, diabetes, rheumatoid arthritis or Human Immuno-deficiency Virus (HIV).

The article includes a reference to the research on the use of wasp venom as a strategy to kill cancer cells selectively lead by Ernest Giralt, head of the Design, Synthesis and Structure of Peptides and Proteins Lab at IRB Barcelona.

Link to 24Hours Naija News 

<p>Meritxell Teixidó and Macarena Sánchez at IRB Barcelona. Image: Santi Cogolludo.</p>
7 Jun 2017

The newspaper “El Mundo” devotes an extensive report to Friedreich's Ataxia through the testimony of Marta, a 13-year-old girl, who began to show the first symptoms of this rare disease when she was only five years old.

The report highlights the research performed by IRB Barcelona aimed to develop an injectable frataxin treatment that can reach the brain. Frataxin is the protein that is reduced in those affected by this disease.

Meritxell Teixidó, the researcher behind the project, which also involves Macarena Sánchez and Ernest Giralt, stresses: "I believe that in 10 or 15years there will be a therapy that turns Friedreich's Ataxia into a chronic disease." And she adds, “...

16 May 2017

The specialist publication The Pharmaceutical Journal devotes a feature article to the efforts being made by researchers worldwide to get drugs across the blood-brain barrier in order to treat central nervous system disorders such as Alzheimer’s disease, depression, and epilepsy. Among the scientists mentioned is Ernest Giralt and the work performed by his lab in search for peptides to be used as Trojan horses to smuggle drugs across the barrier.

The Pharmaceutical Journal, Vol 298, No 7901, online | DOI: 10.1211/PJ.2017.20202723...

<p>This TECNIO seal recognises the IRB Barcelona's Innovation department as a competitive agent in Catalonia’s innovation system</p>
24 Apr 2017

ACCIÓ awards the Institute’s Innovation Department with the quality seal TECNIO and two VALUNI grants for technology transfer projects

<p>Meritxell Teixidó and Macarena Sánchez at IRB Barcelona. Image: Santi Cogolludo.</p>
24 Apr 2017

"El Mundo" publishes an article about an IRB Barcelona research project funded by two patient associations, the international BabelFamily and Asogaf from Granada, that is devoted to finding a treatment for the neurodegenerative disease Friedreich's Ataxia.

Meritxell Teixidó and Macarena Sánchez, scientists behind the project, which also involves Ernest Giralt, explain that the "challenge is to transform it into a chronic disease; the dream would be to halt it or to slow down the degeneration".

Link to El Mundo

<p>Image: Julio Carbó.</p>
4 Apr 2017

The newspaper "El Periódico" has reported on an IRB Barcelona research project on Friedreich’s ataxia disease, funded by the patient and family association, the Babel Family, and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF). The disease is caused by a defect in a gene, frataxin, which results in reduced levels of this protein in the body, particularly affecting the brain, spinal cord and muscles.

The project aims to develop an injectable frataxin treatment that can reach the brain, "like the injection of insulin for diabetics", explains Ernest Giralt,...

<p>Image: PATRICK SEEGER/AFP/Getty Images.</p>
2 Apr 2017

High impact in the international media of Ernest Giralt's latest work presented at the meeting of the American Chemical Society in San Francisco. Giralt, head of the Design, Synthesis and Structure of Peptides and Proteins Lab at IRB Barcelona, is working on transforming a protein from bee venom into a tool that helps treatments get inside the brain. 

“We thought that because the venoms of some animals are able to attack the central nervous system, they should be able to go through the blood-brain barrier and possibly shuttle drugs across it," explains Giralt. 

Link to ...

28 Mar 2017

Radio 5 (RNE) interviews Ernest Giralt, head of the Design, Synthesis and Structure of Peptides and Proteins Lab at IRB Barcelona, and Macarena Sánchez, research associate in the same Lab, about IRB Barcelona’s research to tackle Friedreich’s ataxia. In the interview, Giralt explains that Friedreich’s ataxia is a hereditary degenerative disease that normally appears between the ages of 5 and 25, for which there is currently no cure.

IRB Barcelona’s project, supported by the patient and family association, the Babel Family, and the Asociación Granadina de la ataxia de Friedreich, aims to complete a step necessary to move towards a future frataxin replacement therapy for...

<p>Scheme of therapeutic concept designed by IRB Barcelona. The protein frataxina binds to peptide shuttle (blue), allowing the protein to cross the blood brain barrier and reach the brain (IRB Barcelona)</p>
14 Mar 2017

IRB Barcelona starts a project with the long-term goal to achieve an injectable frataxin treatment able to reach the brain.

Frataxin is the protein that is reduced in those affected by this rare and degenerative disease, which has no cure.

The patients’ associations Babel Family and ASOGAF in Granada provide the funding for the initial 18 months of this challenge.